Cardio Diagnostics Report Identifies Growing Rural Cardiovascular Care Gap Amid Ongoing Workforce Shortages and Access Challenges

Key Terms

telehealth technical

Telehealth is the delivery of healthcare services and consultations remotely using video calls, phone, text messaging, or connected devices to monitor and transmit medical information. It matters to investors because it can reshape how patients access care, lower costs, and create new revenue streams or risks for healthcare providers, insurers and technology companies—similar to how online banking changed financial services—while also exposing businesses to reimbursement and regulatory shifts.

remote monitoring technologies technical

Systems of sensors, devices, software and networks that collect, transmit and analyze data from people, machines or assets without being physically present. Like a home security camera or a wearable fitness tracker that sends status updates, these technologies provide continuous or scheduled data feeds, alerts and reports. Investors care because they can create recurring-service revenues, change cost and risk profiles through early problem detection, and affect regulatory and operational demands for firms that adopt them.

epigenetic-genetic testing medical

Laboratory tests that examine both a person’s DNA sequence (genetic information) and epigenetic marks such as DNA methylation that turn genes on or off; together they can reveal inherited mutations, acquired disease signals, tissue or tumor origin, or biological age. It matters to investors because combining these layers can increase diagnostic accuracy and expand clinical and commercial uses—like reading both a recipe (the genes) and the sticky notes that alter how the recipe is followed (the epigenetic marks)—which affects market size, regulatory review, and partnerships in diagnostics and biotech.

precision-medicine tests medical

Tests that analyze a person’s genes, proteins, or other biological markers to identify which treatments or medical decisions are most likely to work for that individual. Like a road map that shows the best route for one driver, these tests guide doctors toward therapies tailored to a patient’s biology; they matter to investors because their clinical utility, regulatory approval, reimbursement and adoption directly affect the commercial value and market potential of diagnostics, therapies and related companies.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

The report reflects the current state of rural cardiovascular care in America and offers an exclusive roadmap for rural health organizations navigating ongoing workforce shortages and access challenges.

CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, today announced the release of a new edition of the company’s rural health report, “The State of Rural Hospitals and Cardiovascular Care,” aimed at helping rural healthcare leaders, policymakers, and community-based organizations improve cardiovascular care quality and outcomes in rural areas.

Ongoing Workforce Shortages and Access Challenges

The rural healthcare workforce shortage is significant and pervasive, particularly for specialists in cardiovascular medicine: 46% of U.S. counties have no practicing cardiologist. Rural areas have 39.8 physicians per 100,000 residents (compared to 53.3 physicians per 100,000 in urban areas). The persistent shortage of providers in rural regions translates into longer wait times for appointments, limited availability of specialized treatments, and potential delays in receiving critical care.

Access challenges for rural residents are exacerbated by the digital divide: 28% of rural Americans lack broadband access. Inadequate internet infrastructure hinders the potential of telehealth and remote monitoring technologies to bridge the distance between patients and providers. The combined effects of workforce shortages and lack of access to quality cardiovascular care place rural health organizations under mounting strain.

First published in 2024, Cardio Diagnostics’ State of Rural Hospitals and Cardiovascular Care report has been revised to bring renewed focus to persistent challenges faced by rural hospitals and to provide a detailed model for delivering quality cardiovascular care in rural settings. The update also comes as rural health organizations navigate a volatile landscape, including hospital closures and shifts in federal funding, that demands hospitals re-evaluate their strategies for delivering care.

Rural Patients Face Higher Rates of Cardiovascular Disease

While rural areas are challenged by staffing shortages, limited access to specialists, and inadequate infrastructure, the stakes are particularly high for managing cardiovascular disease (CVD). Rural Americans are more vulnerable to CVD than urban counterparts due to:

• Greater geographic isolation
• Lower socioeconomic status
• Reduced access to preventive care
• Increased exposure to cardiovascular risk factors

Smoking rates, for instance, are significantly higher in rural areas (23.3%) compared to urban areas (15.5%). Higher incidence rates place added pressure on rural hospitals to address CVD patient care in their communities while navigating limited budgets and strained resources.

A New Four-Part Model for Delivering Care

The State of Rural Hospitals and Cardiovascular report presents an updated model for organizations seeking to manage CVD in rural areas. This model for delivering high-quality cardiovascular care focuses on early detection and prevention, continuous care management, and personalized interventions through four core areas, including:

• Upskilling primary care clinicians
• Advancing cardiovascular care through epigenetic-genetic testing
• Implementing population-wide strategies to improve community health outcomes
• Integrating remote care options in rural communities

“Rural communities bear a disproportionate burden of cardiovascular disease, and rural health organizations play a vital role in closing that gap. But doing so requires delivering care in a way that accounts for the constraints faced by these communities,” says Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics. “This report examines the driving factors behind these health disparities and the role of new technologies, from virtual cardiac care to precision-medicine tests, in improving access, strengthening early detection, and delivering more personalized care to rural populations.”

Access the full report here.

About Cardio Diagnostics

Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit https://cdio.ai/

Forward-Looking Statements

Certain statements and information included in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, “will likely result,” “expected to,” “will continue,” “anticipated,” “estimate,” “projected,” “intend,” “goal,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, and dependence on results as discussed in the Annual Report on Form 10-K for the period ended December 31, 2025, under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company’s financial performance and could cause the Company’s actual results for future periods to differ materially from any opinions or statements expressed within this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260826128912/en/

Investors
Investor Relations
855-226-9991
investors@cdio.ai

Media & Public Relations
Public Relations
855-226-9991
pr@cdio.ai

Source: Cardio Diagnostics Holdings, Inc.